RecruitingPhase 2NCT06045247

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sponsor

M.D. Anderson Cancer Center

Enrollment

40 participants

Start Date

Jan 5, 2024

Study Type

INTERVENTIONAL

Conditions

Large B-cell Lymphoma

Summary

To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests the drug epcoritamab — which helps your immune system find and destroy cancer cells — combined with standard chemotherapy (R-miniCHOP or R2) for older or less fit patients with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). **You may be eligible if...** - You are 18 or older (this study is particularly relevant for older or less fit patients) - You have newly diagnosed or relapsed DLBCL - You are not able to tolerate full-intensity chemotherapy - Your blood counts and organ function are within the study requirements **You may NOT be eligible if...** - You have active uncontrolled infections - You have received prior epcoritamab or similar drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.